Display Settings:

Format

Send to:

Choose Destination
Drugs Today (Barc). 2012 Nov;48(11):697-703. doi: 10.1358/dot.2012.48.11.1879453.

The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome.

Author information

  • scientific.prousjournals@thomsonreuters.com

Abstract

Clobazam, a 1,5-benzodiazepine, has been available in many European countries since the 1970s, both as an anxiolytic and as an antiepileptic. Recently, it has been marketed in the U.S. for the adjunctive treatment of Lennox-Gastaut syndrome, a seizure disorder accompanied by mental retardation and/or learning difficulties. The condition is usually refractory to many antiepileptic agents. The pivotal phase II and III trials of adjunctive clobazam are reviewed together with its postulated mode of action, pharmacokinetics and drug interaction profile. The data are discussed in terms of existing FDA-approved agents for Lennox-Gastaut syndrome and suggestions for further work.

Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

PMID:
23170305
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk